Sanofi Aventis
Companies that Treat Workers Right Get Good Karma Right Back
4:15PM 8/24/2011
By Selena Maranjian, The Motley Fool
Company News, IBM, Microsoft, Qualcomm, Xerox, Sanofi Aventis, Amazon.com, Cisco Systems, Whole Foods
What's the secret to good worker attendance, retention, productivity, and the ability to attract top-notch recruits? Employee benefits. Which companies thrive and grow their businesses faster than their peers? Same answer: Those that offer better benefits to their workers.
WHO's Swine Flu Pandemic Response Wasn't Influenced by Vaccine Makers
3:30PM 3/10/2011
Health Care, Sanofi Aventis, GlaxoSmithKline, Novartis, Astrazeneca
During the H1N1 swine flu pandemic, much criticism was leveled at World Health Organization officials, accusing their response of being too heavily influenced by the pharmaceutical industry. But according to a panel of independent experts, that wasn't the case.
Japan Finds No Link Between Vaccines and Child Deaths
12:30PM 3/08/2011
Japan's health ministry says it's continuing its suspension of pediatric vaccines made by Pfizer and Sanofi-Aventis, despite finding no connection between the vaccines and the deaths of four children. Both drugmakers are cooperating with the government and expect to be cleared.
Pfizer and Sanofi-Aventis Vaccines Suspended in Japan
1:50PM 3/07/2011
Two pediatric vaccines have been suspended in Japan after the deaths of four children. Shares of Sanofi-Aventis and Pfizer, which make the drugs, have fallen in midday trading.
Pharmaceuticals Look Beyond Medications to Smartphone Apps
11:10AM 2/16/2011
Health Care, Pfizer, Qualcomm, Apple, Sanofi Aventis, Merck, GlaxoSmithKline, Novartis, Cisco Systems
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.
Sanofi to Buy Genzyme in $20.1 Billion Deal
6:30AM 2/16/2011
Company News, Earnings, Genzyme Corporation , Sanofi Aventis
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, the company's multiple sclerosis drug, is a...
Still No Deal Between Sanofi-Aventis and Genzyme
12:45PM 2/11/2011
What is preventing the French pharmaceutical group and U.S. biotech from reaching a merger agreement?
Sanofi-Aventis, Genzyme Are on the Brink of a Merger
10:40AM 2/07/2011
Company News, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News
It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potentially worth $5 to $6 a share.
Just How Much Is Sanofi Aventis Offering for Genzyme?
4:10PM 2/02/2011
Company News, Investing, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News
Just after Genzyme announced that it signed a confidentiality agreement with Sanofi Aventis to allow the French drugmaker to examine its books, leaks about the potential deal started pouring out. The numbers and details vary, so this long battle may not be over yet.
Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas
12:30PM 1/28/2011
Company News, Columns, Health Care, Genzyme Corporation , Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Novartis, Eli Lilly, Astrazeneca
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.
More Stories
Next Page →
Most Popular Stories
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal
Why Your 2012 Tax Bill May Jump By $8,000
Savings Experiment: Tissues vs. Toilet Paper
Wrecks to Riches: Hunting Sunken Treasures from Cape Cod to the Costa ConcordiaDailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Bernanke: Weak housing has hurt consumer...
- Turbo-traders take Bank of America for a ride
- Greece caught between protests, austerity...
- Stocks fall sharply as Greek deal is held up
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- NYSE Euronext profit down on blocked merger...
- Obama call for manufacturing revival a tough...
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
- Morning Wire — US Stock-Index Futures Down Sharply
Follow Us
